If you'd invested $5,000 in this ASX 300 healthcare stock a year ago, you'd now have $30,000!

This stock has made millions for investors over just a few months.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

If I told you that a $5,000 investment in an ASX 300 healthcare stock just one year ago would be worth $30,000 today, you might be a little sceptical. 

After all, that kind of return (500%), especially among the larger companies on the ASX, is an exceptionally rare feat. It certainly beats the pants off most of the popular stocks on the ASX 300, including BHP Group Ltd (ASX: BHP) and Commonwealth Bank of Australia (ASX: CBA).

It's even far greater than the returns of popular growth winners like WiseTech Global Ltd (ASX: WTC), Pro Medicus Limited (ASX: PME) and Xero Ltd (ASX: XRO).

So, what is this highly lucrative ASX 300 stock? Well, it's none other than biotech company Mesoblast Ltd (ASX: MSB).

Yep, one year ago, you could have bought this ASX 300 stock for just 27 cents a pop. Today, those same shares are going for $1.63 each.

That means if one had put $5,000 into Mesoblast shares in December of 2023, they would have been able to amass 18,518 shares (not accounting for brokerage costs). Today, those 18,518 shares would have a value of $30,184.34. Not a bad return for just one year of waiting.

So, how has this ASX 300 healthcare stock delivered such an eye-watering gain in so little time?

How has this ASX 300 healthcare stock rocketed 500% in a year?

Well, Mesoblast regularly experiences the same double-edged sword that most other biotech companies do. Investors tend to flood in when the company is expected to successfully bring a product to market. But equally, investors can bail out en masse if the company experiences setbacks in these endeavours.

A year ago, Mesoblast was in the middle of one of those latter cycles. Its attempts to bring an anti-inflammation drug to market had been met with numerous setbacks, including rejections from government agencies like the US Food and Drug Administration (FDA).

However, all of that changed in late March of this year. As we covered at the time, Mesoblast revealed that the FDA had finally given the company approval to submit a Biologics License Application (BLA) for its 'Ryoncil' remestemcel-L treatment.

The company's shares promptly rocketed close to 200% over the following week or so and have continued to trend upward ever since.

It's clear that investors anticipate that this ASX 300 healthcare stock will continue to find success with Ryoncil and have adjusted the Mesoblast share price accordingly. The company itself shares that confidence, with Mesoblast already initiating a convertible note subscription with its biggest investors that will give it access to additional capital if the FDA gives Ryoncil approval.

Foolish takeaway

Before you turn green with envy though, it's worth noting that this ASX 300 healthcare stock has only been a lucrative investment for a handful of buyers. If you owned this stock for more than a few years, chances are you might still be nursing a loss.

Despite the astonishing gains that Mesoblast shares have made over the past 12 months, this ASX 300 healthcare stock is down by 15% over the past five years. In fact, any investor who bought this company back in August 2020 would still be sitting on a loss of more than 68% today.

Check that out for yourself below before you go:

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALL11 Dec 201911 Dec 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.com.au

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended WiseTech Global and Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »